Supplementary Figure 2 from A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Authors:
  • AZAndrew X. Zhu
    Andrew X. Zhu
  • RFRichard S. Finn
    Richard S. Finn
  • MMMary Mulcahy
    Mary Mulcahy
  • JGJayne Gurtler
    Jayne Gurtler
  • WSWeijing Sun
    Weijing Sun
  • JSJonathan D. Schwartz
    Jonathan D. Schwartz
  • RDRita P. Dalal
    Rita P. Dalal
  • AJAdarsh Joshi
    Adarsh Joshi
  • RHRebecca R. Hozak
    Rebecca R. Hozak
  • YXYihuan Xu
    Yihuan Xu
  • MAMarek Ancukiewicz
    Marek Ancukiewicz
  • RJRakesh K. Jain
    Rakesh K. Jain

Abstract
PDF file - 23K, Waterfall plot depicting the percent change from baseline in serum in alphafetoprotein (AFP)and treatment response in HCC patients after ramucirumab monotherapy. PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated.